A 48-year-old woman with chemorefractory metastatic gastric cancer to the liver was treated in a phase I clinical trial with MetMAb, a monoclonal antibody targeting the Met tyrosine kinase receptor. The primary tumor had high MET gene polysomy and evidence for an autocrine production of hepatocyte growth factor, the growth factor ligand of Met. A complete response was obtained that lasted 2 years...